Bronchiectasis is a chronic lung disease characterized by the permanent widening and damage of the airways, leading to frequent infections and inflammation. According to the Initiative for Chronic Obstructive Lung Diseases, it affects an estimated 1 million individuals worldwide. The disease accounts for a growing burden in respiratory care, with increasing demand for targeted therapies. According to the bronchiectasis pipeline analysis by Expert Market Research, the treatment landscape is witnessing the development of novel antibiotics, anti-inflammatory agents, and biologics. The rising awareness, improved diagnostics, and research focus on precision medicine are expected to drive significant growth in the bronchiectasis drug pipeline in the coming years.
Major companies involved in the bronchiectasis pipeline analysis include Boehringer Ingelheim, Haisco Pharmaceutical Group Co., Ltd., and others.
Leading drugs currently in the pipeline include BI 1291583, CSL787, and others.
The pipeline is expanding due to increased clinical trials of novel anti-inflammatory agents, rising disease awareness, and targeted therapies addressing chronic bacterial infections and mucus clearance.
The Bronchiectasis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into bronchiectasis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for bronchiectasis. The bronchiectasis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The bronchiectasis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with bronchiectasis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to bronchiectasis.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Bronchiectasis is a chronic lung condition marked by irreversible widening of the bronchi, causing mucus buildup, persistent infection, and inflammation. It commonly arises after severe respiratory infections, chronic obstructive pulmonary disease (COPD), or congenital disorders like cystic fibrosis. The disease disrupts mucociliary clearance, leading to repeated cycles of infection and lung tissue damage that progressively impair respiratory function and quality of life.
Bronchiectasis treatment involves airway clearance therapies, mucolytics, inhaled or oral antibiotics, and anti-inflammatory agents. While current options focus on symptom relief and infection control, advanced cases may require lung transplantation due to irreversible airway damage and progressive lung function decline. For instance, in May 2025, Brensocatib emerged as a promising drug in the bronchiectasis pipeline. The ASPEN Phase 3 study demonstrated that Brensocatib significantly reduced exacerbation risks and slowed lung function decline, offering targeted, anti-inflammatory therapy by inhibiting DPP-1.
As per the data released by the Initiative for Chronic Obstructive Lung Diseases, bronchiectasis affects approximately one million individuals globally, including around 400,000 in the United States. As per Hayoung Choi et al., 2024, prevalence rates are notably higher in Asia, 464 per 100,000 in Korea and 1,200 per 100,000 individuals aged ≥40 in China, compared to 67 in Germany and 138 in the USA. The growing incidence and significant economic burden underscore the increasing prevalence driving the bronchiectasis drug pipeline forward.
This section of the report covers the analysis of bronchiectasis drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The bronchiectasis pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total bronchiectasis clinical trials at 47%. It is followed by phase III and IV, each accounting for 20%. The strong presence in Phase II and later phases highlights promising clinical progress, which may drive innovation, attract investment, and enhance treatment options in the bronchiectasis market.
The drug molecule categories covered under the bronchiectasis pipeline analysis include small molecules, monoclonal antibodies, peptides, RNA-based therapies, and vaccines. The bronchiectasis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for bronchiectasis. Anti-inflammatory drug classes are emerging as a promising therapeutic approach in the bronchiectasis drug pipeline. For example, brensocatib, a dipeptidyl peptidase-1 (DPP-1) inhibitor, has shown positive results in reducing pulmonary exacerbations in a Phase III clinical trial. By inhibiting neutrophil serine proteases, the drug aims to control airway inflammation, thereby improving patients' lung function and quality of life over time.
The EMR report for the bronchiectasis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed bronchiectasis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in bronchiectasis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for bronchiectasis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of bronchiectasis drug candidates.
BI 1291583 is a novel oral cathepsin C (CatC) inhibitor currently being evaluated in the Phase III AIRTIVITY® Study sponsored by Boehringer Ingelheim. This study aims to determine whether BI 1291583 can help in reducing flare-ups in adults with bronchiectasis. The drug is designed to target neutrophilic inflammation, a key factor in disease progression, and works by inhibiting CatC activity. Participants are being randomly assigned to receive either BI 1291583 or placebo daily for up to 76 weeks to assess its efficacy, safety, and tolerability.
CSL787, developed by CSL Behring, is a nebulized immunoglobulin G (IgG) therapy currently being evaluated in a Phase 2b trial for adults with non-cystic fibrosis bronchiectasis (NCFB). This multicenter, randomized, double-blind study is assessing the efficacy, safety, and tolerability of CSL787 over 6 to 12 months. The objective is to determine its potential in prolonging the time to first exacerbation. By delivering targeted antibodies directly into the lungs, CSL787 is aiming to reduce infection frequency and improve respiratory health in NCFB patients.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Bronchiectasis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for bronchiectasis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into bronchiectasis collaborations, regulatory environments, and potential growth opportunities.
Upto 30% Off
USD
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share